Share information

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies.

The Company’s ordinary shares of no par value are only admitted to trading on the AIM market of the London Stock Exchange (FARN) from 17 November 2015 and on issuing Nasdaq First North Growth Market (FARON) from 3 December 2019.

Basic share information

The information above is disclosed in accordance with Rule 26 of the AIM Rules for Companies.